Kamal D. Puri

Chief Scientific Officer

Kamal D. Puri has more than 25 years of research and development experience in immunology and oncology. Among his accomplishments was development of Zydelig, a first-in-class PI3K delta inhibitor for the treatment of hematological malignancies. Dr. Puri joined OncoResponse from Celgene where he led a preclinical research group to discover new molecular entities for the immunology pipeline as well as identified and supported new indications for existing portfolio molecules. Prior to Celgene he was Associate Director of Research at Gilead, where he contributed to the approval of Zydelig a first-in-class PI3K delta inhibitor for the treatment of hematological malignancies. Dr. Puri also led internal teams and managed external collaborations to deliver a best-in-class PI3K delta inhibitor and advanced it into clinical development and directed research efforts on multiple discovery projects in inflammation. Prior to Gilead, which acquired Calistoga Pharma, Dr. Puri was Head of Research at Calistoga and was responsible for a wide range of activities including preclinical research and portfolio strategy and biomarker discovery with success in advancing three drug candidates into clinical development for multiple indications. Earlier in his career, Dr. Puri also led drug discovery efforts at ICOS Corporation and CytoTherapeutics.

Talks About
#research #development

Preferred Locations
#NorthAmerica